SelectScience
Join Free
NewsDrug discovery > Lead Discovery

Colorcon Ventures invests in AI provider Atomwise for drug discovery Atomwise

Colorcon, Inc.

Atomwise provides rapid and cost-effective compound screening to address pharmaceutical R&D productivity

27 Aug 2020
Georgina Wynne Hughes
Editorial Assistant

Industry news

Colorcon Ventures, a $50 million corporate venture fund of Colorcon Inc., has invested in Atomwise, a leading provider of artificial intelligence (AI) solutions for drug discovery and inventor of the first deep learning AI technology for structure-based drug design. The company’s technology, called AtomNet®, removes the barriers of physical screening that have limited the success of traditional methods for small molecule drug discovery. AtomNet® currently screens libraries of over 16 billion molecules against novel biological targets in less than two days.

Martti Hedman, CEO at Colorcon, said “Atomwise aligns with the Colorcon Venture fund’s strategic focus on developing transformational technology solutions for the pharmaceutical industry, and Colorcon will be a strong partner for the company. R&D productivity is a major pain point for the pharmaceutical industry. Atomwise is the leading company using AI for small molecule drug discovery, enabling significant time and cost savings for our global customer base. We embrace Atomwise’s approach to partnering with leading pharmaceutical companies in their research & development efforts and are open to strategic alignment with our customers where appropriate.”

Abraham Heifets, Atomwise’s co-founder and CEO, said, “We are pleased to have Colorcon Venture's support as we scale Atomwise. With their support, we will be able to further our mission to make better medicines faster and improve the lives of billions of people.”

For more of the latest science news, straight to your inbox, become a member of SelectScience for free today>>

Links

Colorcon, Inc.

Tags

Biopharmaceutical AdvancesBiopharmaceutical advances follow the development of pharmaceuticals derived from biotechnology, also known as biotechnology medicines. Biopharmaceuticals may be produced from cell lines, plants, or microbial cells. Important considerations of biopharmaceutical use include application, cost, production process and purification.Drug DiscoveryDrug discovery is the process of identifying potential new medications, involving stages such as target identification, compound screening, and preclinical development. It relies on cutting-edge technologies like high-throughput screening, artificial intelligence, and molecular modeling to accelerate the identification of drug candidates. Drug discovery plays a pivotal role in developing new therapies for diseases ranging from cancer to rare genetic disorders. Browse our peer-reviewed product directory to find the latest drug discovery technologies, compare options, check customer feedback, and get pricing directly from manufacturers.PharmaceuticalsPharmaceuticals are medicinal drugs used in healthcare to diagnose, prevent, cure and treat illnesses. Pharmaceuticals that are excreted after use appear in wastewater and can have detrimental effects on the environment.ScreeningUsing robotics, data processing and control software, liquid handling devices and sensitive detectors, screening allows a researcher to quickly conduct millions of chemical, genetic or pharmacological tests.

Related articles